During the last session, Spyre Therapeutics Inc (NASDAQ:SYRE)’s traded shares were 0.79 million, with the beta value of the company hitting 2.85. At the end of the trading day, the stock’s price was $27.70, reflecting an intraday gain of 2.59% or $0.7. The 52-week high for the SYRE share is $47.97, that puts it down -73.18 from that peak though still a striking 65.7% gain since the share price plummeted to a 52-week low of $9.50. The company’s market capitalization is $1.63B, and the average intraday trading volume over the past 10 days was 0.93 million shares, and the average trade volume was 555.37K shares over the past three months.
Spyre Therapeutics Inc (SYRE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.10. SYRE has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.98.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Spyre Therapeutics Inc (SYRE) registered a 2.59% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.59% in intraday trading to $27.70, hitting a weekly high. The stock’s 5-day price performance is -5.14%, and it has moved by -17.80% in 30 days. Based on these gigs, the overall price performance for the year is 166.60%. The short interest in Spyre Therapeutics Inc (NASDAQ:SYRE) is 8.25 million shares and it means that shorts have 21.97 day(s) to cover.
The consensus price target of analysts on Wall Street is $45, which implies an increase of 38.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $40 and $71 respectively. As a result, SYRE is trading at a discount of -156.32% off the target high and -44.4% off the low.
Spyre Therapeutics Inc (SYRE) estimates and forecasts
Statistics show that Spyre Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Spyre Therapeutics Inc (SYRE) shares have gone down -16.01% during the last six months, with a year-to-date growth rate more than the industry average at 85.06% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 75.72% this quarter and then jump 31.25% in the quarter after that. In the rating firms’ projections, revenue will increase 194.86% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.62M as predicted by 8 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 4M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 23.71%. While earnings are projected to return 90.97% in 2024.
SYRE Dividends
Spyre Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.02 million shares, is of FAIRMOUNT FUNDS MANAGEMENT LLC’s that is approximately 8.8668% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $94.47 million.
Also, the Mutual Funds coming in first place with the largest holdings of Spyre Therapeutics Inc (SYRE) shares are Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.1 shares. This amounts to just over 2.14 percent of the company’s overall shares, with a $30.46 million market value. The same data shows that the other fund manager holds slightly less at 1.05, or about 2.04% of the stock, which is worth about $29.02 million.
